Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics

Cell Reports

Volumn 15, Issue 12, 2016, Pages 2705-2718

  Navarro, Paloma ^a   Bueno, Maria J ^a   Zagorac, Ivana ^a   Mondejar, Tamara ^a   Sanchez, Jesus ^a   Mourón, Silvana ^a   Muñoz, Javier ^a   Gómez López, Gonzalo ^a   Jimenez Renard, Veronica ^a   Mulero, Francisca ^a   Chandel, Navdeep S ^b   Quintela Fandino, Miguel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DOVITINIB; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KETONE BODY; ME 344; MONOCLONAL ANTIBODY B20 4.1.1; NINTEDANIB; PHENFORMIN; PROTEIN KINASE B; REGORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; OXYGEN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EX VIVO STUDY; FATTY ACID TRANSPORT; FEMALE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DEGRADATION; LUNG CANCER; METABOLOMICS; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELL RESPIRATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; METABOLOME; MITOCHONDRION; MITOPHAGY; NEOPLASM; NUCLEAR REPROGRAMMING; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELL RESPIRATION; CELLULAR REPROGRAMMING; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS; FEMALE; GLUCOSE; GLYCOLYSIS; HUMANS; KETONE BODIES; METABOLOME; MICE, INBRED C57BL; MICE, NUDE; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; NEOPLASMS; OXYGEN; PHENYLUREA COMPOUNDS; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84975166609     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.052     Document Type: Article

References (36)

1. Baselga J., Costa F., Gomez H., Hudis C.A., Rapoport B., Roche H., Schwartzberg L.S., Petrenciuc O., Shan M., Gradishar W.J. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials 2013, 14:228.
2. Bendell J.C., Patel M.R., Infante J.R., Kurkjian C.D., Jones S.F., Pant S., Burris H.A., Moreno O., Esquibel V., Levin W., Moore K.N. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer 2015, 121:1056-1063.
3. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
4. Crown J.P., Diéras V., Staroslawska E., Yardley D.A., Bachelot T., Davidson N., Wildiers H., Fasching P.A., Capitain O., Ramos M., et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J. Clin. Oncol. 2013, 31:2870-2878.
5. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
6. El-Mir M.Y., Nogueira V., Fontaine E., Avéret N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275:223-228.
7. Foster R., Griffin S., Grooby S., Feltell R., Christopherson C., Chang M., Sninsky J., Kwok S., Torrance C. Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS ONE 2012, 7:e45061.
8. Garcia-Cao I., Song M.S., Hobbs R.M., Laurent G., Giorgi C., de Boer V.C., Anastasiou D., Ito K., Sasaki A.T., Rameh L., et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
9. Heist R.S., Wang X., Hodgson L., Otterson G.A., Stinchcombe T.E., Gandhi L., Villalona-Calero M.A., Watson P., Vokes E.E., Socinski M.A. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J. Thorac. Oncol. 2014, 9:214-221. Alliance for Clinical Trials in Oncology.
10. Hernandez-Agudo E., Mondejar T., Soto-Montenegro M.L., Megias D., Mouron S., Sanchez J., Hidalgo M., Lopez-Casas P.P., Mulero F., Desco M., et al. Monitoring vascular normalization induced by antiangiogenic treatment with F-fluoromisonidazole-PET. Mol. Oncol. 2016, 10:704-718.
11. Hsu C.C., Wang C.H., Wu L.C., Hsia C.Y., Chi C.W., Yin P.H., Chang C.J., Sung M.T., Wei Y.H., Lu S.H., Lee H.C. Mitochondrial dysfunction represses HIF-1α protein synthesis through AMPK activation in human hepatoma HepG2 cells. Biochim. Biophys. Acta 2013, 1830:4743-4751.
12. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
13. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31:2205-2218.
14. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
15. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
16. Kutluk Cenik B., Ostapoff K.T., Gerber D.E., Brekken R.A. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol. Cancer Ther. 2013, 12:992-1001.
17. Li F., Wang D., Zhou Y., Zhou B., Yang Y., Chen H., Song J. Protein kinase A suppresses the differentiation of 3T3-L1 preadipocytes. Cell Res. 2008, 18:311-323.
18. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
19. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., Isachenko N., Fouse S.D., Phillips J.J., Cheresh D.A., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
20. Lunt S.Y., Vander Heiden M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27:441-464.
21. Martin M.J., Hayward R., Viros A., Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012, 2:344-355.
22. Nisancioglu M.H., Betsholtz C., Genové G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010, 70:5109-5115.
23. Oliner J., Min H., Leal J., Yu D., Rao S., You E., Tang X., Kim H., Meyer S., Han S.J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
24. Orecchioni S., Reggiani F., Talarico G., Mancuso P., Calleri A., Gregato G., Labanca V., Noonan D.M., Dallaglio K., Albini A., Bertolini F. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int. J. Cancer 2015, 136:E534-E544.
25. Ostergaard L., Tietze A., Nielsen T., Drasbek K.R., Mouridsen K., Jespersen S.N., Horsman M.R. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res. 2013, 73:5618-5624.
26. Pracharoenwattana I., Zhou W., Smith S.M. Fatty acid beta-oxidation in germinating Arabidopsis seeds is supported by peroxisomal hydroxypyruvate reductase when malate dehydrogenase is absent. Plant Mol. Biol. 2010, 72:101-109.
27. Quintela-Fandino M., Urruticoechea A., Guerra J., Gil M., Gonzalez-Martin A., Marquez R., Hernandez-Agudo E., Rodriguez-Martin C., Gil-Martin M., Bratos R., et al. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). Br. J. Cancer 2014, 111:1060-1064.
28. Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., von Pawel J., Gottfried M., Bondarenko I., Liao M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014, 15:143-155. LUME-Lung 1 Study Group.
29. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., Abrão Miziara J.E., Balint B., De Marinis F., Keller A., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1835-1842.
30. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 2006, 5:741-754.
31. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
32. Soeters M.R., Soeters P.B., Schooneman M.G., Houten S.M., Romijn J.A. Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E1397-E1407.
33. Taylor R.W., Barron M.J., Borthwick G.M., Gospel A., Chinnery P.F., Samuels D.C., Taylor G.A., Plusa S.M., Needham S.J., Greaves L.C., et al. Mitochondrial DNA mutations in human colonic crypt stem cells. J. Clin. Invest. 2003, 112:1351-1360.
34. Viale A., Pettazzoni P., Lyssiotis C.A., Ying H., Sánchez N., Marchesini M., Carugo A., Green T., Seth S., Giuliani V., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014, 514:628-632.
35. Xu L., Stevens J., Hilton M.B., Seaman S., Conrads T.P., Veenstra T.D., Logsdon D., Morris H., Swing D.A., Patel N.L., et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med. 2014, 6:242ra84.
36. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.